The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies.
C. Kohne
Honoraria - Amgen; Merck KGaA; Pfizer
Research Funding - Amgen; GlaxoSmithKline; Merck KGaA; Pfizer; Roche
C. Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Other Remuneration - Merck Serono
S. Heeger
Employment or Leadership Position - Merck KGaA
U. Sartorius
Employment or Leadership Position - Merck KGaA
P. Rougier
Consultant or Advisory Role - Merck KGaA
E. Van Cutsem
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono